Previous Article | Next Article 
Journal of Clinical Microbiology, October 1999, p. 3296-3299, Vol. 37, No. 10
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Comparison of Agar Dilution, Microdilution, E-Test,
and Disk Diffusion Methods for Testing Activity of Cefditoren against
Streptococcus pneumoniae
Linda M.
Kelly,1
Michael R.
Jacobs,2 and
Peter C.
Appelbaum1,*
Departments of Pathology (Clinical
Microbiology), Hershey Medical Center, Hershey, Pennsylvania
17033,1 and Case Western Reserve
University, Cleveland, Ohio 441062
Received 29 April 1999/Returned for modification 15 June
1999/Accepted 25 June 1999
 |
ABSTRACT |
This study evaluated the susceptibility of pneumococci to
cefditoren by agar dilution and microdilution methods (both in air) and
by E-test (AB Biodisk, Solna, Sweden) and disk diffusion methods (both
in CO2). By the three MIC tests, the MICs at which 50 and 90% of isolates were inhibited (MIC50s and
MIC90s) were, respectively, as follows (in micrograms per
milliliter): for the 65 penicillin-susceptible strains tested, 0.016 and 0.03 (by agar dilution), 0.016 and 0.03 (by microdilution), and
0.016 and 0.03 (by E test); for the 68 penicillin-intermediate strains
tested, 0.125 and 0.5 (by agar dilution), 0.125 and 0.5 (by
microdilution), and 0.25 and 0.5 (by E test); and for the 67 penicillin-resistant strains tested, 1.0 and 1.0 (by agar dilution),
0.5 and 1.0 (by microdilution), and 1.0 and 1.0 (by E test). With
tentative cefditoren breakpoints (in micrograms per milliliter) of
2.0 (susceptible), 4.0 (intermediate), and
8.0 (resistant), all
strains were susceptible to cefditoren by agar, microdilution, and
E-test results; with breakpoints of
1.0, 2.0, and
4.0 µg/ml, 97%
of strains were cefditoren susceptible by agar dilution results, 98%
were susceptible by microdilution results, and 99% were susceptible by
E-test results. When microdilution and E-test results were compared to
those from the reference agar dilution method, 191 (95.5%) and 183 (91.5%) of strains gave essential agreement (±1 log2
dilution); 8 (2.7%) minor discrepancies were found for both methods
with a breakpoint of
1.0 µg/ml, and no discrepancies were found
with a breakpoint of
2.0 µg/ml. Disk test results (breakpoint,
1.0 µg/ml) produced 2 major and 30 minor errors, with corresponding
zone diameters (in millimeters) of
20 (susceptible), 17 to 19 (intermediate), and
16 (resistant); a
2.0-µg/ml breakpoint
yielded zone diameters of
16 mm (susceptible). All three methods for
testing the MIC of cefditoren showed excellent correlation.
 |
INTRODUCTION |
Infections caused by pneumococci
with increased MICs of penicillin G and other
-lactam and
non-
-lactam antibiotics have become a problem, both throughout the
United States and elsewhere (1, 5, 6). Previous studies have
documented a rate of penicillin resistance of >30% in cases of
complicated otitis media (5, 6). The problem of
drug-resistant pneumococci is complicated by the ability of this
organism to spread from country to country, and from continent to
continent (12).
Cefditoren is an oral cephalosporin with excellent activity
against penicillin-susceptible, -intermediate and
-resistant pneumococci. Because of its excellent concomitant
activity against Haemophilus influenzae and Moraxella
catarrhalis (2, 4, 7, 10, 15, 17-20), this compound
shows great promise for empiric treatment of otitis media and other
respiratory tract infections and has been successfully used in Japan
for this purpose for several years (17).
Methods used in the routine clinical laboratory to test the activity of
antimicrobials against pathogens, including pneumococci, comprise agar
dilution, broth microdilution, E test (AB Biodisk, Solna, Sweden), and
disk diffusion. The E test, consisting of a continuous stable gradient
of antimicrobial agent corresponding to 15 twofold dilutions on a
strip, has gained wide acceptance as an accurate, routine method for
MIC determination; this has been confirmed by a recently completed
chloramphenicol-based study (8). The technique is less
labor-intensive than standard agar and microdilution methods
(3).
In the present study, we tested the activity of cefditoren against 200 penicillin-susceptible, -intermediate, and -resistant pneumococci by
agar dilution, broth microdilution, E-test, and disk diffusion methods.
 |
MATERIALS AND METHODS |
Bacteria and antimicrobials.
Organisms tested comprised 65 penicillin-susceptible (MICs of
0.06 µg/ml), 68 penicillin-intermediate (MICs of 0.125 to 1.0 µg/ml), and 67 penicillin-resistant (MICs of
2.0 µg/ml) strains, stored in
double-strength litmus milk (Difco Laboratories, Detroit, Mich.) at
70°C prior to testing. Because all strains were stock isolates
subcultured many times, all grew well in air, without needing any
additional CO2 in the incubation atmosphere. Cefditoren powder was obtained from Meiji Seika Kaisha Laboratories, Tokyo, Japan.
No other drug from the same class as cefditoren was included as an
additional quality control.
Interpretive breakpoints.
Cefditoren MICs were interpreted
at tentative susceptible breakpoints of
1 and
2 µg/ml,
intermediate breakpoints of 2 and 4 µg/ml, and resistant breakpoints
of
4 and
8 µg/ml, respectively. Tentative breakpoints of
2
µg/ml (susceptible), 4 µg/ml (intermediate), and
8 µg/ml
(resistant) were suggested to us by the manufacturer, based upon the
fact that following a 200- or 400-mg dose of cefditoren as cefditoren
pivoxil, maximal cefditoren concentrations in plasma are achieved at
2.5 h after the dose, with maximum concentrations in serum of 2.8 and 4.8 µg/ml, respectively. Additionally, with either of these
doses, cefditoren concentrations in plasma can be expected to exceed
0.5 µg/ml for 5 to 8 h and to exceed 1.0 µg/ml for 4 to 6 h. The drug has a terminal elimination half-life in plasma of 1.5 to
3 h (11). However, because no definite breakpoints have
been recommended yet for cefditoren by the National Committee for
Clinical Laboratory Standards (NCCLS), we decided to also analyze
data based upon breakpoints 1 dilution lower than the ones suggested.
Agar dilution MICs.
Agar dilution MIC tests were performed
according to standard methods (6). Media consisted of
Mueller-Hinton agar (Becton Dickinson Microbiology Systems,
Cockeysville, Md.) (supplemented with 5% sheep blood), with cefditoren
incorporated at concentrations from 0.002 to 16 µg/ml in doubling
dilutions. Inocula were prepared by suspending growth from overnight
cultures in Mueller-Hinton broth (BBL) to a turbidity of a 0.5 McFarland standard. Final inocula contained 104
organisms/spot. Plates were inoculated with a Steers replicator with
3-mm inoculating pins and incubated overnight at 35°C in air. The
lowest concentration of antibiotic showing no growth was read as the
MIC. Quality control organisms included Staphylococcus aureus ATCC 29213, Escherichia coli ATCC 25922, and
Streptococcus pneumoniae ATCC 49619 and were included in
each run. Antimicrobial-containing plates were prepared in-house,
stored at 4°C, and used within 7 days of preparation. All strains
were tested concomitantly for penicillin susceptibility with each run.
The stability of the plates was proven by performing selected tests on
the day of preparation and 1 week later. In all cases, identical
results were obtained.
Microdilution MICs.
MICs were determined by the broth
microdilution method recommended by the NCCLS (13), using
cation-adjusted Mueller-Hinton broth (BBL) supplemented with 5% lysed
horse blood for pneumococci. Trays were prepared freshly in-house,
frozen at
70°C if necessary, and used within 2 days of preparation.
For MIC determinations, suspensions with a turbidity equivalent to that
of a 0.5 McFarland standard were prepared by suspending growth from
blood agar plates in 2 ml of sterile saline. Suspensions were further
diluted 1:10 to obtain a final inoculum of 5 × 105
CFU/ml. Trays were incubated for 20 to 24 h in ambient air at 35°C. Standard quality control strains (as described above) were included in each run. The stability of trays after storage was tested
and confirmed as described above.
E-test (AB Biodisk) MICs.
Mueller-Hinton plates supplemented
with 5% sheep blood were inoculated with a 0.5 McFarland standard of
suspension harvested from plates, and cefditoren E-test strips (0.016 to 256 µg/ml) were placed on each. The MIC was determined from the
intersection of the ellipse of growth inhibition with the strip
(3). Where colonies occurred within the inhibition ellipse,
the higher value was used as the MIC. E-test plates were incubated
under 5 to 10% CO2 at 35°C for 20 to 24 h.
Disk diffusion testing.
Disk diffusion testing was by
standard NCCLS methods (14) using Mueller-Hinton plates
supplemented with sheep blood and inoculated with a 0.5 McFarland
standard. Cefditoren disks (5 µg; Becton Dickinson Microbiology
Systems) were applied. After overnight incubation at 35°C, zone
diameters were read with the aid of calipers. Disk diffusion test disks
were incubated under 5 to 10% CO2, as recommended by the
NCCLS (14).
Interpretation of results.
A MIC within ±1 log2
dilution compared to the MIC determined by the agar dilution reference
method was interpreted as essential agreement. Very major discrepancies
occurred when the reference method showed resistance and the
comparative method showed susceptibility; major discrepancies occurred
when the reference method showed susceptibility and the comparative
method showed resistance (3). Minor discrepancies occurred
when an intermediate result was obtained with one method and a
resistant or susceptible result was obtained with the other. Cefditoren
quality control values were those recommended by the manufacturer and
validated by previous studies in our laboratory (18, 19).
Values with S. pneumoniae ATCC 49619 were 0.03 to 0.06 µg/ml (by agar dilution), 0.03 to 0.06 µg/ml (by microdilution), 0.06 µg/ml (by E test), and 25 to 28 mm (disk diffusion).
 |
RESULTS |
The MICs (in micrograms per milliliter) at which 50% and 90% of
isolates were inhibited (MIC50s and MIC90s) for
penicillin G were, respectively, 0.03 and 0.06 for
penicillin-susceptible strains, 0.5 and 1.0 for penicillin-intermediate
strains, and 2.0 and 4.0 for penicillin-resistant strains. Cefditoren
MIC50s and MIC90s were, respectively, very
similar by all three methods (Table 1).
For penicillin-susceptible strains, MIC50s and
MIC90s (in micrograms per milliliter) were 0.016 and 0.03 (by agar dilution), 0.016 and 0.03 (by microdilution), and
0.016 and
0.03 (by E test); corresponding values for penicillin-intermediate
strains were 0.125 and 0.5 (by agar dilution), 0.125 and 0.5 (by
microdilution), and 0.25 and 0.5 (by E test); and those for
penicillin-resistant organisms were 1.0 and 1.0 (by agar dilution), 0.5 and 1.0 (by microdilution), and 1.0 and 1.0 (by E test).
With breakpoint concentrations (in micrograms per milliliter), based
upon pharmacokinetic and pharmacodynamic criteria (see above) of
2
(susceptible), 4 (intermediate), and
8 (resistant), all strains were
susceptible to cefditoren by agar, broth microdilution, and E test
methods; with breakpoints of
1, 2, and
4, 97% of strains were
cefditoren susceptible and 3% of strains were intermediate by agar
dilution; 98% were susceptible and 2% were intermediate by
microdilution, and 99% were susceptible and 1% were intermediate by E
test (Table 2).
Disk diffusion testing with a
1-µg/ml cefditoren-susceptible
breakpoint yielded 2 major errors (1%) and 30 minor errors (15%), applying corresponding zone diameters (in millimeters) of
20 (susceptible), 17 to 19 (intermediate), and
16 (resistant) (Fig. 1). At a
2-µg/ml susceptible
breakpoint, all strains were susceptible and had zone diameters of
16
mm (Fig. 1). Although 30 minor errors is excessive, none of them would
significantly impact the clinical situation. Strains for which
cefditoren MICs were
0.03 µg/ml produced zone diameters of 25 to 35 mm, those for which MICs were 0.06 to 0.5 µg/ml had zone diameters of
18 to 36 mm, and those for which MICs were
1.0 µg/ml had zone
diameters of 16 to 24 mm (Fig. 1).

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Scatterplot of cefditoren MICs by agar dilution versus
disk diffusion zone diameters. Each symbol indicates one isolate.
Dashed line shows regression line. Disk diffusion breakpoints for
cefditoren at MIC breakpoints of 1, 2, and 4 µg/ml are shown and
are 20, 17 to 19, and 16 mm, respectively.
|
|
When broth microdilution and E-test results were compared to reference
agar dilution results, 191 (95.5%) and 183 (91.5%) of the strains
showed essential agreement; eight (2.7%) minor discrepancies were
found for both methods with a breakpoint of
1 µg/ml. Because no
cefditoren MICs of >2 µg/ml were observed, discrepancies for
intermediate and resistant strains could not be assessed (Table
3).
 |
DISCUSSION |
Previous studies have documented excellent antipneumococcal
activity of cefditoren, compared with that of other oral
-lactams, with arithmetic mean MIC90s of
0.06, 0.5, and 1 µg/ml
against penicillin-susceptible, -intermediate, and -resistant
pneumococci, respectively (2, 4, 7, 10, 18-20).
Bactericidal activity (99.9% killing) occurred with cefditoren against
all pneumococcal strains tested at
0.5 µg/ml after 24 h,
irrespective of their penicillin susceptibility. Additionally,
cefditoren showed 99% killing of all strains after 6 h at test
concentrations of
4 times the MIC (19). Cefditoren MICs
are significantly lower and its kill kinetics are slightly more rapid
than those for other oral cephalosporins (9, 16, 18, 19).
Results of this study confirm the excellent activity of cefditoren
against penicillin-susceptible, -intermediate, and -resistant pneumococci and show a very good correlation among agar dilution, broth
microdilution, and E-test results for all strains. Incubation of E-test
plates in CO2, compared with that in air for agar and microdilution, did not significantly influence results.
 |
ACKNOWLEDGMENT |
This study was supported by a grant from TAP Holdings, Inc.,
Deerfield, Ill.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pathology, Hershey Medical Center, 500 University Dr., Hershey, PA
17033. Phone: (717) 531-5113. Fax: (717) 531-7953. E-mail:
pappelbaum{at}psghs.edu.
 |
REFERENCES |
| 1.
|
Breiman, R. F.,
J. C. Butler,
F. C. Tenover,
J. A. Elliott, and R. R. Facklam.
1994.
Emergence of drug-resistant pneumococcal infections in the United States.
JAMA
271:1831-1835[Abstract/Free Full Text].
|
| 2.
|
Canton, R.,
J. Liñares,
J. Martinez-Beltran,
F. Tubau,
F. Almaraz,
F. Alcaide, and F. Baquero.
1994.
Bactericidal activity of cefditoren (ME-1206) on Streptococcus pneumoniae and Streptococcus of the viridans group, abstr. E11, p. 28.
In
Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
|
| 3.
|
Clark, C. L.,
M. R. Jacobs, and P. C. Appelbaum.
1998.
Antipneumococcal activities of levofloxacin and clarithromycin as determined by agar dilution, microdilution, E-test, and disk diffusion methodologies.
J. Clin. Microbiol.
36:3579-3584[Abstract/Free Full Text].
|
| 4.
|
Fremaux, A.,
G. Sissia,
I. Brumpt, and P. Geslin.
1993.
Cefditoren (ME-1206), a new cephalosporin: in vitro activity against penicillin susceptible and resistant pneumococci, abstr. 998, p. 289.
In
Program and abstracts of the 18th International Congress of Chemotherapy.
|
| 5.
|
Friedland, I. R., and G. H. McCracken, Jr.
1994.
Management of infections caused by antibiotic-resistant Streptococcus pneumoniae.
N. Engl. J. Med.
331:377-382[Free Full Text].
|
| 6.
|
Jacobs, M. R., and P. C. Appelbaum.
1995.
Antibiotic-resistant pneumococci.
Rev. Med. Microbiol.
6:77-93.
|
| 7.
|
Jones, R. N.,
D. J. Biedenbach,
M. A. T. Croco, and M. S. Barrett.
1998.
In vitro evaluation of a novel orally administered cephalosporin (cefditoren) tested against 1249 recent clinical isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae.
Diagn. Microbiol. Infect. Dis.
31:573-578[Medline].
|
| 8.
| Jones, R. N., and M. A. Pfaller.
Unpublished data.
|
| 9.
|
Liñares, J.,
T. Alonso,
J. L. Pérez,
J. Ayats,
M. A. Domínguez,
R. Pallarés, and R. Martín.
1992.
Decreased susceptibility of penicillin-resistant pneumococci to twenty-four -lactam antibiotics.
J. Antimicrob. Chemother.
30:279-288[Abstract/Free Full Text].
|
| 10.
|
Miyazaki, S.,
Y. Miyazaki,
A. Tsuji,
M. Nishida, and S. Goto.
1991.
In vitro antibacterial activity of ME1207, a new oral cephalosporin.
Antimicrob. Agents Chemother.
35:1691-1694[Abstract/Free Full Text].
|
| 11.
| Mulford, D. (TAP Holdings, Inc.). 1999. Personal
communication.
|
| 12.
|
Munoz, R.,
J. M. Musser,
M. Crain,
D. E. Briles,
A. Marton,
A. J. Parkinson,
U. Sorensen, and A. Tomasz.
1992.
Geographic distribution of penicillin-resistant clones of Streptococcus pneumoniae: characterization by penicillin-binding protein profile, surface protein A typing, and multilocus enzyme analysis.
Clin. Infect. Dis.
15:112-118[Medline].
|
| 13.
|
National Committee for Clinical Laboratory Standards.
1997.
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. NCCLS publication no. M7-A4.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 14.
|
National Committee for Clinical Laboratory Standards.
1997.
Performance standards for antimicrobial disk susceptibility testing. NCCLS publication no. M2-A6.
National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 15.
|
Negri, M. C.,
M. I. Morosini,
E. Loza, and F. Baquero.
1994.
In vitro selective concentrations of cefditoren for penicillin resistant Streptococcus pneumoniae populations, abstr. E15, p. 28.
In
Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
|
| 16.
|
Nelson, C. T.,
E. O. Mason, Jr., and S. L. Kaplan.
1994.
Activity of oral antibiotics in middle ear and sinus infections caused by penicillin-resistant Streptococcus pneumoniae: implications for treatment.
Pediatr. Infect. Dis. J.
13:585-589[Medline].
|
| 17.
|
Shimada, K.,
S. Shinkai,
I. Komiya, and T. Matsumoto.
1989.
Phase-I clinical studies on a novel orally active cephem antibiotic, ME1207, abstr. 366, p. 162.
In
Program and abstracts of the 29th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
|
| 18.
|
Spangler, S. K.,
M. R. Jacobs, and P. C. Appelbaum.
1996.
Activities of RPR 106972 (a new oral streptogramin), cefditoren (a new oral cephalosporin), two new oxazolidinones (U-100592 and U-100766), and other oral and parenteral agents against 203 penicillin-susceptible and -resistant pneumococci.
Antimicrob. Agents Chemother.
40:481-484[Abstract].
|
| 19.
|
Spangler, S. K.,
M. R. Jacobs, and P. C. Appelbaum.
1997.
Time-kill studies on susceptibility of nine penicillin-susceptible and -resistant pneumococci to cefditoren compared with nine other -lactams.
J. Antimicrob. Chemother.
39:141-148[Abstract/Free Full Text].
|
| 20.
|
Tamura, A.,
R. Okamoto,
T. Yoshida,
H. Yamamoto,
S. Kondo,
M. Inoue, and S. Mitsuhashi.
1988.
In vitro and in vivo antibacterial activities of ME1207, a new oral cephalosporin.
Antimicrob. Agents Chemother.
32:1421-1426[Abstract/Free Full Text].
|
Journal of Clinical Microbiology, October 1999, p. 3296-3299, Vol. 37, No. 10
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lodise, T. P., Kinzig-Schippers, M., Drusano, G. L., Loos, U., Vogel, F., Bulitta, J., Hinder, M., Sorgel, F.
(2008). Use of Population Pharmacokinetic Modeling and Monte Carlo Simulation To Describe the Pharmacodynamic Profile of Cefditoren in Plasma and Epithelial Lining Fluid. Antimicrob. Agents Chemother.
52: 1945-1951
[Abstract]
[Full Text]
-
Tenhagen, B.-A., Koster, G., Wallmann, J., Heuwieser, W.
(2006). Prevalence of mastitis pathogens and their resistance against antimicrobial agents in dairy cows in Brandenburg, Germany.. J DAIRY SCI
89: 2542-2551
[Abstract]
[Full Text]
-
Clark, C. L., Nagai, K., Dewasse, B. E., Pankuch, G. A., Ednie, L. M., Jacobs, M. R., Appelbaum, P. C.
(2002). Activity of cefditoren against respiratory pathogens. J Antimicrob Chemother
50: 33-41
[Abstract]
[Full Text]
-
Reinert, R. R., Al-Lahham, A., Lutticken, R.
(2001). In vitro activity of cefditoren against clinical isolates of penicillin-susceptible and penicillin-intermediate strains of Streptococcus pneumoniae isolated in Germany, 1992-1998. J Antimicrob Chemother
48: 279-281
[Abstract]
[Full Text]
-
Wright, D. H., Brown, G. H., Peterson, M. L., Rotschafer, J. C.
(2000). Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother
46: 669-683
[Abstract]
[Full Text]